Oncobiologics Appoints Lawrence A. Kenyon as Chief Financial Officer

CRANBURY, N.J., Sept. 16, 2015 /PRNewswire/ -- Oncobiologics, Inc. announced the appointment of Lawrence A. Kenyon as its Chief Financial Officer (CFO), effective September 15, 2015.

Mr. Kenyon is an accomplished executive with extensive experience managing the financial and business operations of emerging and established private and public biopharmaceutical companies. His most recent positions were at Arno Therapeutics, Inc. (Chief Operating Officer and CFO) and Tamir Biotechnology, Inc. (interim President, Chief Executive Officer and CFO), where he successfully assisted in advancing clinical drug development programs. Prior to these positions, Mr. Kenyon served as CFO for Par Pharmaceutical Companies, Inc., a publicly traded generic pharmaceutical company, where he restructured financial and information technology operations, realigned financial priorities and streamlined efficiencies between finance and operational management. Prior to his tenure at Par, Mr. Kenyon was CFO at two publicly traded biopharmaceutical companies, Alfacell Corp. and NeoPharm, Inc., where he successfully closed several financing rounds that enabled the companies to advance their respective clinical programs. Mr. Kenyon obtained a bachelor's degree in business administration at the University of Wisconsin-Whitewater and is a certified public accountant in Illinois.

Mr. Kenyon's appointment follows Oncobiologics' appointment of Kenneth M. Bahrt, M.D., FACR, as its Chief Medical Officer, in July 2015, as Oncobiologics continues to expand its management team as it advances its product candidates through development. Dr. Bahrt has demonstrated success in clinical product development, particularly in the area of immunology, at NPS Pharmaceuticals, Inc., Savient Pharmaceuticals, Inc. and Genentech, Inc.

About Oncobiologics, Inc. and its BioSymphony™ Platform
Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Its initial focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. Oncobiologics is advancing its pipeline of eight biosimilar products, two of which are currently in clinical development.  Led by a team of biopharmaceutical experts, Oncobiologics operates from a state-of-the-art fully integrated research and development, and manufacturing facility in Cranbury, New Jersey.  Oncobiologics employs its BioSymphony™ platform to address the challenges of biosimilar development and commercialization by developing high quality mAb biosimilars in an efficient and cost-effective manner on an accelerated timeline. For more information, please visit www.oncobiologics.com.

CONTACTS:

Business Development: 
Stephen J. McAndrew, Ph.D.
Sr. Vice President, Business Strategy & Development
Oncobiologics, Inc.
[email protected]

Media: 
Marissa Goberdhan
Russo Partners, LLC
[email protected]

Investors:  
Robert Flamm, Ph.D.
Russo Partners, LLC
[email protected]   

SOURCE Oncobiologics, Inc.

Related Links

http://www.oncobiologics.com